Elsevier

American Heart Journal

Volume 122, Issue 5, November 1991, Pages 1492-1495
American Heart Journal

Brief communication
Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome

https://doi.org/10.1016/0002-8703(91)90604-GGet rights and content

First page preview

First page preview
Click to open first page preview

References (10)

There are more references available in the full text version of this article.

Cited by (35)

  • Acute postoperative biventricular failure associated with antiphospholipid antibody syndrome

    2004, British Journal of Anaesthesia
    Citation Excerpt :

    In cases where thrombosis continues despite adequate anticoagulation, additional treatment is aimed either at preventing antibody formation or reducing antibody titres and may include corticosteroids, immunosuppressive agents, i.v. immune globulin, or plasmapheresis. Tissue plasminogen activator has been used successfully in one case report of APS with ST changes and normal coronary arteries.32 Thrombosis in APS typically affects large vessels.

  • Antiphospholipid thrombosis syndromes

    2003, Hematology/Oncology Clinics of North America
  • Management of thrombosis in antiphospholipid antibody syndrome

    2001, Rheumatic Disease Clinics of North America
    Citation Excerpt :

    Nevertheless, the standard of care is usually heparin followed by warfarin. APS patients with myocardial infarction can be considered as candidates for thrombolytics,12,13 angioplasty, or coronary stents.14 Peripheral arterial thromboses can be treated with heparin (or thrombolytics) or angioplasty.

View all citing articles on Scopus
View full text